Beroni Group Limited New R&D Centre in High-Tech Hub in Zhuhai, China

Sydney, Australia (ABN Newswire) - Beroni Group (OTCMKTS:BNIGF) (NSX:BTG), an Australia-based diversified biopharmaceutical enterprise focused on the research, development, innovation and commercialization of therapies and products for treatment of global diseases, is pleased to announce that it has signed a contract to build a new Research & Development ("R&D") centre in the Zhuhai National High-Tech Industrial Development Zone in China. Beroni aspires to build a state-ofthe-art facility with new preclinical research labs, manufacturing process development labs, and a GMP pilot manufacturing plant.

The new R&D centre -- the first R&D site for Beroni -- will help the Company develop new drugs and medicines to cater for the vast needs of the Chinese market. To start with, the Company will occupy about 4,000 square metres (44,000 square feet) of office space for setting up the GMP plant and laboratories. Construction of the new R&D facilities is expected to be completed towards the end of the second quarter, and the entire R&D centre is expected to be ready in the second half of this year. Beroni intends to commit US$10 million to support the clinical trials in the new R&D facility. A new company, Beroni Pharmaceutical (Guangdong) Co., Ltd, has been established for this new venture with Beroni owning 80% of the entity's shares and a local investor owning the other 20% shares. The Company will bring professional staff, scientists, technicians, and support teams together into a state-of-the-art hub for innovation and development of the company's future products and services.

Beroni has a drug development pipeline focusing on oncology and immunotherapy. It is moving ahead with the Phase II clinical trial of the anti-cancer molecular drug, PENAO later this year and is scheduled to commence the clinical trials for a few cellular therapies including gamma delta T cell, DC vaccine, and protein modifier R8. It is also currently studying the use of single-domain antibodies for treatment of coronavirus diseases.

"Establishing a new R&D centre in Zhuhai will allow us to expand our R&D capabilities and accelerate our innovative pipeline," said CEO Jacky Zhang. "In the future, we plan to establish additional R&D centres around the world to advance the discovery and development of new innovative product candidates."

The Zhuhai National High-Tech Industrial Development Zone Valley, established in 1992, is one of the top biotech hubs in China and is home to hundreds of innovative biotechnology and biopharmaceutical companies. It covers an area of 139 square kilometres and boasts a convenient transportation network with the Beijing-Zhuhai Expressway, Western Guangdong Coastal Expressway and Guangzhou-Zhuhai Intercity MRT passing through the area. Ideally placed for business opportunities, the zone has the location advantage of being within the "One-Hour Economic Circle" of the Pearl River Delta.



About Beroni Group Limited:

Beroni Group (NSX:BTG) (OTCMKTS:BNIGF) is an international biopharmaceutical enterprise dedicated to the innovation and commercialization of drugs and therapies to combat various global diseases such as cancer and infectious diseases. Its diversified portfolio is comprised of a US FDA approved virus diagnostic kit, an e-commerce platform for the sale of pharmaceutical products and a development pipeline targeting oncology and cell therapies. Beroni has operations in Australia, United States, China and Japan. To learn more about Beroni, please visit www.beronigroup.com.



Source:
Beroni Group Limited



Contact:
Dragon Gate Investment Partners LLC
Tel: +1(646)-801-2803
Email: BNIGF@dgipl.com

News Provided by ABN Newswire via QuoteMedia

BTO:CA,BTG
The Conversation (0)
Stack of gold bars with red downward arrow on white background.

Gold Price Hits 14 Month Low as Fed Rate Hike Fears Strengthen US Dollar

The gold price continued its downward decline Friday (November 20) as investors reassessed US Federal Reserve policy, raising questions about whether the precious metal's longer-term rally can regain momentum.The fall representing a 14-month low forced the yellow metal in sight of the US$3,500... Keep Reading...
Steve Barton, mine site.

Steve Barton: Gold, Silver Selloff Not Over, My Next Price Targets

Steve Barton, host of In It To Win It, shares his thoughts on gold and silver's recent price declines, saying he sees further downward momentum ahead. "I don't think this level is going to hold," he said about gold. "I think we're going back to this zone right here, which is around US$3,350 to... Keep Reading...
Red world map with declining financial graph lines and bar charts.

Are We in a Recession? Predictions, Signs and Strategies

"Never miss out on an opportunity like a recession" — Jack Welch, former chair and CEO of General Electric.US President Donald Trump’s plans to overhaul the current global trade structure through sweeping tariffs have once again ignited recession fears. With both businesses and consumers... Keep Reading...
Joe Cavatoni, gold bars.

Joe Cavatoni: Gold Outlook Solid, Top Price Drivers for 2027

Joe Cavatoni, senior market strategist, Americas, at the World Gold Council, shares his thoughts on gold's move below US$4,000 per ounce and what's driving the yellow metal. "Right now (I'm) closely watching what's going to play out in the rate market, how bonds are going to perform and also... Keep Reading...
Gareth Soloway, gold, silver and Bitcoin.

Gareth Soloway: Gold, Silver, Bitcoin and More — My Price Calls for 2027

Gareth Soloway, chief market strategist at VerifiedInvesting.com, shares his outlook for gold, silver, oil and Bitcoin prices in 2027, including key price points he's watching. He also gives his thoughts on gold in the near term, noting that holding above US$3,885 per ounce — a level gold has... Keep Reading...

Interactive Chart

Latest Press Releases

Related News